Analyst Ratings For bluebird bio (NASDAQ:BLUE)
Today, BMO Capital Markets raised its price target on bluebird bio (NASDAQ:BLUE) to $222.00 per share.
Some recent analyst ratings include
- 2/22/2018-Sanford C. Bernstein Reiterated Rating of Market Perform.
- 2/1/2018-Canaccord Genuity Reiterated Rating of Buy.
- 1/25/2018-Leerink Swann was Downgraded by analysts at Leerink Swann from a “Outperform ” rating to a ” Market Perform” rating. They now have a $194.00 price target on the stock, up previously from $162.00 .
- 1/9/2018-Oppenheimer Reiterated Rating of Hold.
- 12/21/2017-CIBC initiated coverage with a Market Perform rating.
- On 2/2/2018 David Davidson, Insider, sold 4,000 with an average share price of $202.36 per share and the total transaction amounting to $809,440.00.
- On 1/30/2018 Jason Cole, Insider, sold 25,000 with an average share price of $195.91 per share and the total transaction amounting to $4,897,750.00.
- On 1/30/2018 Susanna Gatti High, COO, sold 17,262 with an average share price of $195.91 per share and the total transaction amounting to $3,381,798.42.
- On 1/8/2018 David Davidson, Insider, sold 3,522 with an average share price of $173.61 per share and the total transaction amounting to $611,454.42.
- On 1/5/2018 Jason Cole, Insider, sold 1,129 with an average share price of $173.38 per share and the total transaction amounting to $195,746.02.
- On 1/5/2018 Nick Leschly, CEO, sold 5,435 with an average share price of $173.38 per share and the total transaction amounting to $942,320.30.
- On 1/3/2018 David Davidson, Insider, sold 6,000 with an average share price of $180.30 per share and the total transaction amounting to $1,081,800.00.
Recent Trading Activity for bluebird bio (NASDAQ:BLUE)
Shares of bluebird bio closed the previous trading session at 199.75 down -7.65 3.69% with 195.0500030517578 shares trading hands.